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was assumed when generic alternatives became available. RESULTS: The Spanish
population with arterial hypertension over 35 years treated with combinations of
ARBII and CCB with or without DIU was estimated at 990,000 patients in 2010,
expecting to rise to 1.17 million patients in 2013. Total treatment costs for hyper-
tension treatment over the next 3 years were estimated at €1.638 million before the
introduction of SevikarHCT® and at €1.649 million after introduction.
CONCLUSIONS:Although the introduction of SevikarHCT® adds incremental costs
for the Spanish NHS, a decrease in the overall economic burden with or without the
introduction of SevikarHCT® was observed from 2010. These budget savings can be
explained by the effect in price drop caused by the availability of generics.
PCV43
BUDGET IMPACT OF THE IMPLEMENTATION OF A TREATMENT PROTOCOL FOR
PULMONARY ARTERIAL HYPERTENSION IN A REFERRAL HOSPITAL
Vega-Coca MD1, Flores S2, Bautista J3
1Andalusian Agency for Health Technology Assessment, Seville, Seville, Spain, 2Andalusian
Agency for Health and Technology Assessment, Seville, Andalucia, Spain, 3Hospital Virgen del
Rocio, Sevilla, Sevilla, Spain
OBJECTIVES: To examine evidence on efficacy and safety of oral drugs for pulmo-
nary arterial hypertension (PAH). Analyze their utilization and their cost. To pro-
pose a treatment protocol based on efficacy, safety and efficiency. Calculate the
estimated budget impact after its implementation. METHODS: A search was con-
ducted in MEDLINE, EMBASE and Cochrane Database. Systematic reviews and
meta-analysis of bosentan, ambrisentan, sildenafil or tadalafil in PAH (functional
class II/III) were included. Their utilization was analyzed retrospectively in patients
with primary or associated with connective tissue diseases pulmonary hyperten-
sion that started treatment during 2008 to 2010. The annual cost per patient for
each alternative was calculated (standard dosage). A treatment protocol was de-
veloped, based on efficacy, safety, and efficiency. The incremental cost for each
drug, and the potential savings if all patients start their treatment with the most
cost-effective were calculated. RESULTS: No evidence was found to support the
superiority of any treatment over another, in terms of efficacy and/or safety. Sev-
enteen patients started treatment during the study period (47% bosentan, 41.2%
sildenafil, 11.8% ambrisentan). Estimated annual cost per patient: 30,987.07,
26,861.93, 7,807.74 and 6,865.65 €, for bosentan, ambrisentan, sildenafil and tada-
lafil, respectively. In absence of significant differences in efficacy or safety, the
treatment protocol was based on efficiency (sildenafil tadalafil ambrisentan
bosentan). Incremental cost (compared to sildenafil): 24,121.42, 19,996.28 and
€942.09 for bosentan, ambrisentan and tadalafil, respectively. Estimated potential
savings with implementation of protocol: 77,654.64 €/ year. CONCLUSIONS: No
evidence supports the superiority of any treatment over another, so they could be
considered equivalent therapeutic alternatives. Bosentan is most widely used drug
in naïve patients. The cost associated with bosentan/ambrisentan is markedly
greater to sildenafil/tadalafil. Establishing a protocol that prioritizes sildenafil/
tadalafil use would help to more efficient management of resources.
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OBJECTIVES: To ascertain the cost-utility of patient self-management (PSM) com-
pared to standard monitoring among long-term oral anticoagulation therapy pa-
tients in Austria. METHODS: A Markov model was used to combine international
effectiveness data and local cost and mortality data in a life-long simulation (closed
cohort with a mean baseline age of 67 years). Costs were calculated using informa-
tion on healthcare contacts from healthcare professionals and associated tariffs.
Costs for standard monitoring were based on monthly visits to primary/outpatient
settings and determination of PTZ levels. PSM costs included costs of the hand-
held device, materials, training and regular healthcare check-ups. Costs associated
with complications (thrombotic and haemorrhagic events) in primary-care, acute
care and rehabilitation settings were also considered, since complications occur at
different rates between monitoring strategies. Sensitivity analyses were
performed. RESULTS: PSM was associated with 15.9 life years or 10.7 QALYs com-
pared to 14.6 life years or 9.4 QALYs with standard monitoring. Costs per patient for
the entire period were €7,873 for PSM, €8,170 for monitoring by GPs, €8,354 for
monitoring by community-based consultants and € 8,810 for monitoring at a hos-
pital out-patient clinic. PSM was the dominant strategy for both the cost per life-
year gained and cost per QALY analysis. Although PSM led to higher initial costs
(between €908 and €916 per patient in the first year), follow-up costs were lower
(between €228 and €235 per patient per year thereafter) due to lower frequency of
health care visits. Standard monitoring was associated with monitoring costs of
between €273 and €391 per patient per year. CONCLUSIONS: Encouraging suitable
patients to self-manage leads to better health outcomes and lower costs. In Austria,
initial costs are compensated by lower complication rates and associated costs and
lower monitoring expenses. Cost-savings to the health sector could be accrued as
soon as 3 years after patients switch strategies.
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OBJECTIVES: PLATO was a multi centered, double blind, randomized study that
included 18,624 ACS patients from 43 countries, comparing ticagrelor  aspirin
versus clopidogrel aspirin. The PLATO demonstrated that ticagrelor was superior
on the primary composite endpoint: myocardial infarction, stroke, cardiovascular
death (HR 0.84, 95% CI: 0.77 to 0.92) without an increase in major bleedings com-
pared to clopidogrel, and whether the strategy of choice was invasive or conserva-
tive. The aim of this analysis is to estimate direct health care costs from a Spanish
health care perspective (excluding drug costs because ticagrelor price has not yet
been established). METHODS: Resource utilization was pre specified in the PLATO
trial and included hospitalization bed days, investigations, interventions and blood
products. Direct health care costs per patient at 12 months were estimated by
multiplying the resource use with Spanish unit costs derived from the Spanish
database e-salud, the GRDs of the Ministry of Health, published literature, and the
CMBD 2008. RESULTS: Ticagrelor resulted in numerically fewer bed days (mean
difference per patient 0.21, 95% CI -0.16 to 0.59), PCIs (mean difference per patient
0.01, 95% CI -0.01 to 0.03) and CABGs (mean difference per patient 0.01, 95% CI: 0.00
to 0.01). Ticagrelor is associated with €341 reduction per patient (95% CI: 31 to 652)
in healthcare costs at 12 months compared to clopidogrel. The reduction in health-
care costs was mainly due to fewer hospital days and cardiovascular interventions
in the ticagrelor group. The reduction in cost increased over the 12-month treat-
ment period consistent with the rate of clinical events over time in the PLATO
study. CONCLUSIONS: Treatment with ticagrelor is associated with cost savings in
patients with ACS at 12 months compared with clopidogrel (excluding drug costs)
from a Spanish health care perspective. However, the total cost savings will depend
on drug price, data not available yet.
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OBJECTIVES: To assess the clinical and economic burden of major bleeding in
abdominal surgery patients. METHODS: A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a medical claims database. Patients in-
cluded in the study were admitted to the hospital with abdominal surgery as their
primary procedure. Patients’ demographic, clinical and discharge statuses were
compared using Chi-square testing and standardized differences. Risk-adjusted
health care visits and costs were estimated using the General Linear Model (GLM).
Potential risk factors for venous thromboembolism (VTE) events were selected
using the Cox Proportional Hazard Regression Model. RESULTS: In patients identi-
fied with abdominal surgery (n49,355), 773 (1.57%) suffered major bleeding in the
6-month follow-up period. Compared with patients who did not suffer major bleed-
ing, patients who did were more likely to be older, have higher Charlson Comor-
bidity Index (CCI) scores and have other comorbid conditions such as cancer. The
percentage of patients who had baseline emergency room (ER) visits was also
higher in the major bleeding group. After risk-adjustment for pre-specified covari-
ates, inpatient ($21,573 vs. $10,954), outpatient ($12,891 vs. $7,852) and pharmacy
costs ($2,025 vs. $1,901) were higher for patients who suffered major bleeding. In
addition, patients with major bleeding events had higher readmission rates (0.11%
vs. 0.03%) during the follow-up period. CONCLUSIONS: Since the health care costs
of patients with major bleeding events were significantly higher than those of
patients without, it is important for individual hospitals to improve major bleeding
prophylaxis therapy.
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OBJECTIVES: To estimate clinical outcomes, health care utilization and cost bur-
den of patients who suffered a transient ischemic attack (TIA) during the 180 days
after a diagnosis of non-valvular atrial fibrillation (NVAF) and compare it with
patients who did not. METHODS: Based on 2005-2007 US insurance claim files,
patients aged 65 years and older who have had two or more primary diagnoses of
NVAF, occurring within 30 days of one another, were selected. The 180 days fol-
low-up event rates, health care facility use and costs for patients with and without
a TIA were compared. Risk adjustment was performed using the propensity score
matching (PSM) method with the ProbChoice™ algorithm. RESULTS: A total of
18,575 patients were identified with NVAF, of which 163 (0.88%) suffered a TIA
during the 180 days after the NVAF diagnosis. Patients were not significantly dif-
ferent in terms of gender, region, and baseline comorbid conditions. After PSM
risk-adjustment for pre-specified covariates, outpatient emergency room (ER) vis-
its (85.89% vs. 48.47% p0.0001), cardiovascular-related length of stay (6.59 days vs.
5.57 days, p0.0001) and ischemic stroke events (89.57 vs. 8 /100 person years,
p0.0001) were higher for patients who suffered a TIA compared to those who did
not. Although risk-adjusted outpatient office visit, international normalized ratio
(INR) testing, Coumadin outpatient visit, drug and other costs did not differ signif-
icantly between the two groups, patients who suffered a TIA had significantly
higher inpatient ($21,740 vs. $22,663, p0.0001) and total ($31,675 vs. $18,045,
p0.0001) expenditures. CONCLUSIONS: After adjusting for patient clinical and
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demographic characteristics, total health care utilization and cost burden were
higher for patients who suffered a TIA after an NVAF diagnosis, relative to patients
who did not.
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OBJECTIVES: To compare clinical outcomes and cost burden of patients who suf-
fered a stroke during the 180 days after diagnosis of non-valvular atrial fibrillation
(NVAF) with patients who did not. METHODS: Based on 2005-2007 US Medical
insurance claim files, patients aged 65 years and older who have had two or more
primary diagnoses of NVAF, occurring within 30 days of one another, were selected.
The 180-day follow-up mortality rate, health care facility use and costs for patients
with and without incidences of stroke were compared. Risk adjustment was per-
formed using the propensity score matching (PSM) method with the ProbChoice™
algorithm. RESULTS: Out of patients who were identified with and without NVAF
pre-stroke (n18,195), 541 (2.97%) suffered a stroke during the 180 days after the
NVAF diagnosis. After PSM risk-adjustment for pre-specified covariates, mortality
(7.39% vs. 1.07% p0.0001), outpatient emergency room (ER) visits (80.59% vs.
48.11% p0.0001), readmission rates (1.85% vs. 0.40%, p0.0001), transient isch-
emic attacks (44 vs. 8 /100 person years), and intracranial hemorrhage rates (71 vs.
7/100 person years) were all higher for patients who suffered a stroke compared to
those who did not. Although risk-adjusted outpatient ER costs and office visit costs
did not differ significantly between the two groups, patients who suffered a stroke
had significantly higher inpatient ($24,231 vs. $15,137, p0.0001) and total ($33,439
vs. $13,782, p0.0001) expenditures. CONCLUSIONS: Most of the adverse events
analyzed were higher for patients who suffered a stroke after an NVAF diagnosis
relative to patients who did not. Total health care utilizations and health care costs
were also significantly increased.
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OBJECTIVES: To ascertain the direct costs related to hospitalization in the Physical
Medicine Service and Rehabilitation of a tertiary referral hospital during the year
2009. METHODS: An epidemiological, observational retrospective study was car-
ried out in the Central University Hospital of Asturias –HUCA-, Spain. All patients
admitted to the Rehabilitation Unit (RU) and suffering from a cerebrovascular dis-
ease (CVD), brain injury (BI), spinal cord injury (SCI) or amputations were included.
RU services was acting as secondary referral level -SRL- in case of BI and CVD. In
contrast, SCI and amputations were attended in the same RU as tertiary referral
level-TRL-. A cost-analysis following hospital perspective was performed recording
all health resources at patient level. Next, direct costs were calculated attaching a
published cost to each resource. Socio-demographic and clinical variables were
registered to describe the sample and to facilitate external comparisons. Mean
costs per patient were calculated considering each of the pathologies and compar-
ing SRL and TRL. Costs were defined in 2009 Euros. Chi2 test was used to compare
socio-demographic and clinical variables between groups. Next, parametric (Stu-
dent’s t test and ANCOVA analysis) and non parametric analysis (bootstrapping)
were applied to estimate economic differences between groups. RESULTS: A total
of 243 patients admitted to RU were assessed. Mean age (SD) was 59.62 years (1.41)
and 71.2% males. Mean cost per patient (SD): BI(n 15) 28,837.87(23,998.80); CVD(n
116), 31,751.05(19,151.26); SCI(n 105), 27,635.39(24,856.55); amputations(n 7),
24,342.86(5,426.48). Mean SRL cost was significantly higher than TRL:
31,417.48(19,681.03) and 27,429.61(24,106.37), respectively (p 0.013). Total anual
SRL cost was 4,115,751.43 and 3,072,167.39 TRL. CONCLUSIONS: Forty-six percent
of total activity in the RU is related to TRL requiring 43% of total expenditure.
Further research comparing this policy with early discharge and home rehabilita-
tion should be implemented to promote the efficiency of this service.
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OBJECTIVES: Atrial fibrillation (AF) is a prevalent disease that often requires costly
hospital care, but the cost of hospital utilization has not been reported in Canada.
The purpose of this study was to estimate the cost of hospital utilization for AF in
Canada. METHODS: Three national administrative databases (Discharge Abstract
Database, Same Day Surgery and National Ambulatory Care Reporting System) for
the year 2007/08 were used to capture admissions, same day surgeries and emer-
gency department (ED) visits. Provincial/territorial data were extrapolated to the
national level using age-gender census information where necessary. Records with
a most responsible diagnosis (MRD) of AF, atrial flutter or a secondary diagnosis of
AF were included in the analysis. Hospital costs were estimated by applying an
average cost per weighted case to the resource intensity weight that was provided
for each admission/visit, and then adding the physician fees for admissions, sur-
geries and interventions. All cost estimates are expressed in 2010 Canadian dollars.
RESULTS: In 2007/08, the number of hospital admissions with MRD of AF was
10,924 for men and 11,899 for women, same day surgeries was 3,910 for men and
1,797 for women and ED visits were 29,754 for men and 28,312 for women. The
average cost per admission was $6,718 with an average length of stay of 5.7 days.
The average cost of same day surgery was $3,524 and an ED visit was $849. The total
hospital cost for patients with AF was $815M; $710M for hospital admissions,
$72.9M for ED visits, and $31.8M for same day surgery. Most of the costs were for
hospital admissions when AF was listed as a comorbidity ($558.2M, 69%)
CONCLUSIONS: The substantial cost burden of AF in the acute care sector is driven
by the consequences of AF, while the costs for specific treatments for AF are rela-
tively low.
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OBJECTIVES: Acute coronary syndrome (ACS) is the most important clinical con-
sequence of coronary artery disease and a leading cause of death worldwide. This
study aims to assess the costs of ACS from a social and health insurance perspec-
tive evaluating direct costs, production losses and intangible costs in terms of
quality adjusted life years (QALYs) lost. METHODS: A bottom-up incidence ap-
proach was used. ACS-Patients with one or more ACS events were extracted from
a national hospital database and from mortality statistics. Remaining life years of
surviving patients were modelled on age, gender and life expectancy statistics.
Inpatient costs include acute care and rehabilitation in 2008. Outpatient costs in-
clude costs for ambulance, visits to GP and cardiologist, outpatient diagnostics,
medication and rehabilitation. Production losses were calculated according to the
human capital approach, including absenteeism, permanent disability and prema-
ture death. Intangible costs were calculated based on literature data. Cost data are
derived from official price lists, literature and experts. Validation of clinical data
was conducted using the AMIS-PLUS registry. RESULTS: A total of 14,955 patients
experienced a total of 16,815 ACS events in 2008; 2,752 died as a consequence of
these. This resulted in 19,064 hospital stays with an average length of stay in acute
care of 8.9 days per patient. Total direct costs amounted to 690 Mio Swiss Francs
(CHF) for the society and 523 Mio CHF for health insurers. Forty-four percent belong
to inpatient and 56% to outpatient services. Production losses were 515 Mio. CHF
and intangible costs resulted in 37,457 QALYs lost. Average total direct costs and
production losses per patient were 80,873 CHF. Results appear robust in sensitivity
analysis. CONCLUSIONS: ACS causes considerable costs in terms of direct medical
expenditures, lost production and premature death, even without taking into ac-
count costs for its chronic consequences such as congestive heart failure.
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OBJECTIVES: Atrial fibrillation (AF) is the commonest cardiac arrhythmia found in
clinical practice with an increasing prevalence in the aging population. Local esti-
mates vary from 1.2 to 2.5%. The objective of our study was to evaluate the burden
of AF on secondary care costs in England, which is responsible for substantial
cardiovascular morbidity and mortality. METHODS: AF and stroke event and cost
data captured in Hospital Episode Statistics(HES), between 2006 and 2009, was
analysed to estimate the trends in hospital episodes in England. RESULTS: A total
of 193,742 patients with a primary or secondary diagnosis of AF were hospitalised
in 2009, representing a 19% increase in AF patients on the previous 3 years. During
this period there were 239,746 hospital spells with a diagnosis of AF; a 22% increase
from 2006-2009. The total inpatient cost attributable to AF increased from £353
million in 2006 to a total of £361 million in 2009. As a proportion of all admissions,
AF admissions were 1.1% in 2006 to 1.2% in 2009 and represented 1,162,213 bed days
occupied in 2006 versus 1,108,283 in 2009. In 2009, of the 193,742 patients with a
diagnosis of AF, 5,391 subsequently had a stroke. This gives a conversion rate from
AF to stroke of 3.1% of patients – up from 2.5% in 2006. During this same period, the
average length of stay for the stroke patient with AF has increased from 38 days to
43 days (higher than those patients who have only had a stroke). CONCLUSIONS:
Despite advances in both AF and stroke management, AF presents a significant and
increasing burden on hospital care in England. New initiatives are needed to detect
AF early and prevent hospital admissions or to manage AF in rapid access arrhyth-
mia clinics where appropriate therapies to manage the rate, rhythm and cardio-
vascular risks can be dispensed without needing admission.
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OBJECTIVES: The objective of this study was to quantify, for the first time in a
Spanish population, the time and cost burden of informal care for pts with heart
failure. METHODS: A descriptive analysis of a multicenter, prospective observa-
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